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I. Abstract 
 
Background: Prostate cancer is a disease of aging, particularly in nations of affluence, 
with risk increasing several hundred-fold from age 40 to 75.  Indeed, as one of the most 
common malignancies in Americans, it is a significant health care burden.  In addition, 
prostate cancer treatment strategies result in significant negative impacts on quality of life 
for a growing number of senior citizens.  Therefore, prevention strategies are critically 
needed. Accumulating research suggests that several dietary factors may reduce risk, 
such as consumption of cruciferous vegetables, soy, and tomatoes. Our laboratory work 
and others suggests that specific components of these foods demonstrate anticancer 
properties, such as inhibition of cancer cell proliferation and enhanced sensitivity to 
activation of cell death programs (apoptosis).   
 
Objective: We hypothesize that bioactive phytochemicals can be combined in specific 
combinations within carefully designed functional foods that meaningfully contribute to 
the prevention of prostate cancer progression. We evaluated the combined effects of the 
bioactive components in arugula in cell-based studies, using erucin, sulphoraphane and 
genistein. 
 
Design: Prostate cancer cells (PC3) were treated in vitro with 5-20 uM of sulforaphane, 
5-20 uM of erucin, and 5-40 uM of genistein, alone and in specific combinations. Cell 
viability was measured at 24, 48 and 72 hours after treatment using the Sulforhodamine B 
method to investigate the combined contribution of proliferation and apoptosis.  In 
addition, preliminary cell cycle analysis by flow cytometry was conducted to determine 
the impact of erucin and genistein alone and in combination on cell cycle progression.    
 
Results: Cruciferous vegetables components at 20 uM such as sulforaphane (high in 
broccoli) and erucin (high in arugula) were equally effective at 72 hours with 75% vs 
80% viability respectively.  Genistein (20 uM) from soy foods was also modestly 
effective, reducing viability by 35%. Erucin and genistein display unique time and dose 
dependent profiles of inhibition.  
 
Significance: Laboratory in vitro studies may help us define combinations of 
phytochemicals that have combined anticancer effects, helping us to design novel food 
products (e.g. a vegetable juice) for future human studies.   
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II. Introduction 
 
Among U.S. men, prostate cancer (PCA) is the most common non-cutaneous malignancy, 
the leading cancer diagnosis and the second leading cause of death from cancer (Fowke, 
2012). PCA is a disease of aging, particularly in nations of affluence, with risk increasing 
several hundred-fold from age 40 to 75. Fortunately, with screening the vast majority of 
prostate cancers can be detected and cured by radiation or surgery.  Yet, treatment is 
associated with significant risk of morbidity, particularly sexual dysfunction, 
incontinence, and injury to the bladder or rectum that has a negative impact on quality of 
life for a growing number of men.  Autopsy studies demonstrate pathologic diagnosis of 
prostate cancer as early as the third decade of life, prior to any clinically significant 
diagnostic symptoms (Sánchez-Chapado et al, 2003). Yet, the average age of diagnosis is 
67 (Howlader et al, 2011).   
 
 
  
Figure 1. Prevalence of prostate cancer by decades (Sánchez-Chapado et al, 2003). 	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Androgen production, which initiates during puberty, undoubtedly plays a significant role 
in the initiation and progression of prostate carcinogenesis (Wang et al, 2011). Therefore, 
for some, prostate cancer development occurs over decades, providing an ideal window 
of opportunity for dietary and nutrition based interventions to prevent and delay the 
progression of prostate cancer.  The high prevalence and mortality, along with the length 
of tumor development time, make PCA a target for prevention, and strategies are 
critically needed.  
 Our laboratory has focused upon a number of preventive strategies related to 
chemopreventive pharmaceuticals, nutrients, or foods. To date, we have developed a 
novel tomato soy juice that has been used in a clinical trial of 60 men for four weeks prior 
to prostatectomy with excellent compliance. Preliminary data clearly demonstrates a dose 
dependent increase in tomato phytochemicals in the serum of these patients. Analysis is 
underway for soy phytochemicals in human blood, urine and prostate tissue samples. We 
aim to develop the next generation of vegetable juice and currently hypothesize that the 
addition of cruciferous vegetables and all that they provide may provide an added benefit 
for the anti prostate cancer activities.  
 Cruciferous vegetables include broccoli, broccoli sprouts, cauliflower, and 
arugula among others. These vegetables are known for their rich source of 
phytochemicals with bioactivity on a number of processes associated with 
carcinogenesis.  We are particularly interested in arugula, which is a rich source of the 
isothiocyanate (ITC) erucin, with the ultimate objective of adding an extract of arugula to 
our tomato-soy juice that is now in clinical trials.  Our hypothesis is that erucin will 
enhance the anticancer properties of other phytochemicals.  To date, no studies have 
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investigated the influence of arugula extracts and erucin in models of prostate cancer.   
Data from cell culture and rodent models of prostate cancer have suggested anticancer 
properties of the isothiocyanate sulforaphane and broccoli extracts. We tested the impact 
of erucin compared to sulforaphane, alone and in combination with other phytochemicals 
from soy, on the growth of prostate cancer cells in vitro. 
 
Bioactive Phytochemicals and Nutrients: 
 
 Myrosinase hydrolyzes glucosinolates (GSLs) to isothiocyanates (ITCs) and other 
products during food processing or when the plant is broken down.  The breakdown 
products of GSLs may play roles as antioxidants, which in part contribute to the 
protective effects on cancer (Kim et al, 2004).  Myrosinase enzymes catalyze the 
conversion of inactive glucosinolate precursors to the active isothiocyanate form, such as 
the conversion of the GSL glucoerucin to the active isothiocyanate erucin (ER). When 
consuming cruciferous vegetables, myrosinase is released during chewing to hydrolyze 
GSLs into isothiocyanates (Melchini & Traka, 2010). Figure 2 shows this mechanism, 
along with the oxidation of ER to sulforaphane (SFN). 
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Studies investigating the compounds found in cruciferous vegetables have 
demonstrated significant anti-carcinogenic effects.  Eruca sativa, also known as arugula 
or rocket salad, is rich not only in fiber, iron, and vitamins A and C, but also sulforaphane 
and erucin (Kim et al, 2007). One of the most prominent glucosinolates (GSLs) present in 
arugula leaves is glucoraphanin, which is converted to sulforaphane upon hydrolysis. In 
arugula leaves, at least 12 GSLs have been identified, including glucoerucin at a signal 
intensity of deprotonated molecules ratio of 420 m/z, and glucoraphanin at 436 m/z. It 
has been hypothesized that glucoraphanin levels are slightly higher in arugula than 
glucoerucin due to the oxidation of glucoerucin to form glucoraphanin. In a seed extract 
of arugula, only 3 GSLs have been identified, and glucoerucin is overwhelmingly the 
7R[LQV 2010,               
 
 
596 
demonstrated [53]. In a study carried out by Lamy and colleagues there is evidence of the strong 
antigenotoxic effect of (UXFD V. in benzo[a]pyrene exposed human hepatoma (HepG2) cells [54]. 
Recently, chemoprotective properties of rocket leaves on human colon cancer cells have been also 
investigated [55] (Table 1). 
Figure 1. The 4-(methylthio)butyl isothiocyanate, erucin (ER), is a reduced analog of the 
4-(methylsulfinyl)butyl isothiocyanate, sulforaphane (SF), and its formed both from 
enzymatic hydrolysis of glucoerucin, a glucosinolate found at high levels in rocket species 
((UXFD VDWLYDMill., 'LSORWD[LV WHQXLIROLD L.) and LQ YLYR reduction of SF, derived from 
broccoli (%UDVVLFDROHUDFHD L. ssp LWDOLFD). 
 
Table 1. Experimental evidence supporting health promoting activity of rocket salad species. 
Rocket species  Health promoting activity  Experimental Model  Reference  
(UXFDVDWLYD(seeds)  antidiabetic activity  rats  [48]  
(UXFDVDWLYD(seeds)  
 
protective effect against 
HgCl2-induced nephrotoxicity  
rats  [49]  
(UXFDVDWLYD(seeds, 
sprouts) 
(UXFDVDWLYD(leaves)  
(UXFDVDWLYD(leaves)  
antioxidant activity  LQYLWURass y  [50]  
 
[51] 
[52]  
(UXFDVDWLYD(leaves)  anti- ulcer activity  albino rats  [53]  
(UXFDVDWLYD  
 
 
antigenotoxic activity  human hepatocellular 
carcinoma HepG2 cell 
line  
[77]  
(UXFDVDWLYD(leaves) 
'LSORWD[LVWHQXLIROLD 
(leaves)  
chemopreventive activity  human colonic cancer 
HT-29 cell line  
[55]  
Figure 2. The 4-(methylthio)butyl isothiocyanate, erucin (ER), is a reduced analog of the 
4-(methylsulfinyl)butyl isothiocyanate, sulforaphane (SF), and its formed both from 
enzymatic hydrolysis of glucoerucin, a glucosinolate found at high levels in rocket species 
(Eruca Sativa) and in vivo reduction of SF, derived from broccoli (brassica oleracea) 
(Melchini & Traka, 2010).	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most abundant glucosinolate present, at more than 7 times the amount of glucoraphanin 
(Cataldi et al, 2007).  
Glucosinolates can be derived from amino acids like methionine, phenylalanine, 
and tryptophan. The bitter flavor characteristic of cruciferous vegetables comes from the 
presence of GSLs and their breakdown products (Kim et al, 2007). These compounds 
have clear effects on cell proliferation in vitro. For example, sulforaphane induced G2/M 
phase cell cycle arrest in prostate cancer cells by inhibiting a checkpoint kinase 2-
mediated phosphorylation during cell division (Kim & Singh, 2009). For in vivo studies, 
ITCs must be provided in doses that are safe and provide bioavailable concentrations of 
the bioactive phytochemicals. Oral administration of 5.6 uM SFN three times a week 
retarded PC-3 growth in mice, and this amount of SFN is easily generated through diet as 
100g of broccoli contains up to 40 uM SFN (Singh, 2004). Previous studies have shown 
that exposure of human prostate cancer cells to SFN results in G2/M phase cell cycle 
arrest via checkpoint kinase 2-mediated phosphorylation of cell division (Singh et al, 
2009).  
Proposed mechanisms of action for the anti-cancer activity of these ITCs include 
epigenetic modifications to receptor mediated alterations in transcriptional activity.  SFN 
may inhibit testosterone induced cancer progression by inhibiting the expression of 
androgen receptor (AR) and its transcriptional activity in human prostate cancer cells 
(Kim & Singh, 2009). Epigenetics is the study of heritable changes in gene activity, and 
in recent years studies have shown that genes can be turned on and off, making the 
epigenome as important as changes in DNA. The ability of isothiocyanates like 
sulforaphane to target epigenetic patterns may make it an effective agent of 
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chemoprevention in carcinogenesis (Ho et al 2009). Reversing the acetylation of histones 
is one mechanism that may be involved.  Histone deacetylase inhibitors (HDAC) are a 
cancer chemoprevention strategy (Sargeant et al, 2008), and SFN from cruciferous 
vegetables has been shown to inhibit HDAC activity in prostate cancer cells (Ho et al 
2009).   
As stated previously, we are ultimately interested in the ability of isothiocyanates 
to enhance the anti-cancer activity of other food constituents in the modification of 
prostate cancer risk.  Genistein is the most abundant isoflavone in soy and one of the 
more potent bioactives in soy.  Genistein has the ability to inhibit growth in vitro of both 
androgen-dependent and independent prostate cancer cells (Zhao et al, 2009). 
Epidemiological studies have shown that Asian men who consume a diet high in soy 
isoflavones have a lower incidence of prostate cancer (Zhao et al, 2009). The mechanism 
of genistein’s anti-carcinogenic activity includes the induction of apoptosis and inhibition 
of angiogenesis.  Genistein resulted in cell death in as low of a dose as 5 uM and 
treatment with 10 uM of genistein resulted in a 27% increase in PC3 cells in the G2/M 
phase. (Zhao et al, 2009). One of the objectives of this study is to determine if the 
combination of bioactive soy phytochemicals with cruciferous vegetable ITC would have 
enhanced anti-carcinogeneic activities. 
Benefits of Functional Food Based Cancer Prevention Strategies: 
 Nutrition based interventions are potentially useful strategies to prevent and delay 
the progression of prostate cancer. There is a significant period of time during which 
dietary and nutrition based interventions may impact the carcinogenesis process, and 
combinations of bioactive rich foods consumed over extended periods of time have the 
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potential to improve prognosis. Much of what we know about nutrition and cancer 
prevention comes from epidemiological studies or preclinical laboratory models. 
However, our team is developing functional foods which provide specific combinations 
of bioactive phytochemicals in a safe palatable form.  Our ultimate goal is to develop 
functional foods integrating arugula with tomatoes and soy for prostate cancer prevention 
clinical trials.  
 To date, there are no studies evaluating the combined anti-prostate cancer effects 
of cruciferous vegetable phytochemicals with soy phytochemicals. Therefore, before 
proceeding with the development of a second generation vegetable juice adding 
cruciferous vegetables to the existing novel tomato soy juice, we aim to test the ability of 
these phytochemicals to enhance the activity of genistein in a pre-clinical model of 
prostate cancer.  
 
III. Methods 
 
 We treated the prostate cancer cell line PC3 with sulforaphane, erucin, genistein, 
and a control (DMSO) in a factorial design. The effects of these treatments on the PC3 
cells were evaluated in a time and dose dependent manner. The growth of these cells was 
measured to determine how sulforaphane, erucin and genistein affect cell viability and 
cell cycle progression. Cell viability was quantified by Sulforhodamine	  B	  (SRB)	  assay	  after	  24,	  48	  and	  72	  hours	  of	  exposure	  to	  sulforaphane,	  erucin,	  and	  genistein.	  Cells	  were	  seeded	  in	  96-­‐well	  flat-­‐bottomed	  plates	  for	  24h	  then	  treated	  with	  erucin	  at	  concentrations	  between	  5-­‐20	  uM,	  genistein	  at	  5-­‐40	  uM,	  and	  sulforaphane	  at	  5-­‐20	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uM,	  with	  three	  replicates	  each.	  For pre-treatment studies, cells were treated for 24h for 
pre-treatment, then media exchanged with new treatment. Viability was quantified by 
fixing cells and staining with Sulforhodamine B solution  (In vitro toxicology assay, 
Sigma Aldrich) to determine the protein content of	  the	  treated	  cells	  was	  measured,	  which	  yielded	  growth	  curves	  that	  show	  the	  effects	  of	  these	  compounds	  on	  cell	  proliferation.	  
 Cell cycle analysis was performed on cells plated for 24 hours prior to treatment, 
then cultured for 24, 48, and 72h in the presence of 10uM erucin and 10um Genestein 
alone and in combination, with treatments replenished daily. Cells were collected, rinsed, 
fixed with ice-cold 70% ethanol and stained with 50ug/ml propidium iodide in PBS 
containing 0.1% Triton-X and 0.2mg/ml RNAse A for 30 minutes at room temperature. 
Flow cytometry was conducted on a FACSCalibur (BD Biosciences, Franklin Lakes, NJ) 
instrument and cell cycle modeling analysis by FlowJo (Tree Star, Inc, Ashland, OR)  	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IV. Results 
 Previous studies have shown that SFN inhibits the viability of prostate cancer 
cells. We first aimed to compare the effectiveness of ER and SFN on PC-3 cells (Kim 
and Singh, 2009). Both ER and SFN significantly inhibited cell viability in a time and 
dose dependent manner. We found that time and dose had a p-value <0.001, meaning that 
there was a statistical difference in the cell viability between 24, 48 and 72 hours, as well 
as a statistically significant decrease in viability between different doses. There was no 
difference between drugs overall, with a p>0.05, meaning ER and SFN were equally 
effective. All doses were significant for each drug at 48 and 72 hours. At 24, 48 and 72 
hours, 20 uM ER reduced cell viability by 39.3%, 56.2% and 78.6% respectively. At 24, 
48 and 72 hours, 20 uM SFN reduced cell viability by 35.4%, 60% and 74.6% 
respectively.   Figure 3 shows ER and SFN in a time and dose dependent manner at 24, 
48 and 72 hours. Since SFN and ER were equally effective at these time points and doses, 
we chose to use ER in the remainder of our studies, because it is more abundant in 
arugula. 
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Figure 3. Erucin and sulforaphane equally inhibit prostate cancer cell viability. 
Both erucin and sulforaphane inhibit cell viability in a dose and time dependent manner 
(p<0.001). At equal concentrations, there is not a significant difference between the two 
compounds. *indicates significance (p<0.05) from control.  	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 We next tested the ability of addition of 10 uM GEN to enhance the dose 
dependent inhibition of ER on viability. The PC-3 cells were treated with a control of 
DMSO, 10uM GEN alone, 10uM GEN in combination with 5, 10 and 20uM ER, and 5 
and 20uM ER alone. All of these different treatments were significantly inhibited 
viability compared to control (P <0.001). The main effect of time was also significant 
with a p=0.013. At 24, 48 and 72 hours, 20 uM ER in combination with 10 uM GEN 
decreases viability by 45.3%, 58% and 67.1% respectively, compared to 20 uM ER alone, 
which decreased viability by 53.3%, 61% and 68.5%. Figure 4 shows these relationships 
in a dose dependent manner over 24, 48 and 72 hours.	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Figure 4. Genistein does not enhance the inhibitory activity of erucin.  
Genistein, at a 10uM concentration in vitro did not further enhance the inhibitory activity of 
erucin. Each dose of treatment was significant (P<0.001) compared to the control, but 
treatment of erucin alone was not significantly different from treatment in combination with 
10uM genistein at any dose or timepoint (p>0.050). *indicates significance (p<0.050) from 
control. 	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 We next tested the dose dependent effect of Genistein on viability and if erucin at 
10 uM enhances this effect. We kept ER constant at 10 uM and added GEN in 5, 10, 20, 
and 40 uM. The main effects of time, addition of ER and GEN dose response were 
significant (p<0.001). At 24, 48 and 72 hours, 20 uM GEN in combination with 10 uM 
ER decreased cell viability by 39.8%, 46.7%, and 56.4% respectively, compared to 20uM 
GEN alone which decreased viability by 17%, 32%, 45.3% at 24, 48 and 72 hours. At 24, 
48 and 72 hours, 40 uM GEN in combination with 10 uM ER decreased cell viability by 
45.8%, 49.5%, and 64.3% respectively, compared to 40 uM GEN alone which decreased 
viability by 27.6%, 45.7%, and 54.8% at 24, 48 and 72 hours. Figure 5 shows the 
relationship over 24, 48 and 72 hours. 	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Figure 5. Genistein has a modest dose and time dependent inhibitory effect on prostate 
cancer viability that is enhanced by the addition of Erucin.  
Genistein, alone, displays a significant  main effect of time and does dependent inhibition in 
viability (p<0.001). Erucin (10uM) enhances the activity of genistein (p<0.001) and there is a 
modest interaction between erucin and genistein at 72h (p=0.036).  *indicates significance 
(p<0.050) from no genistein; # indicates significance (p<0.05) from no erucin  	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 We conducted a cell cycle analysis by flow cytometry on PC-3 cells treated daily 
with a control of DMSO, 10 uM ER, 10 uM GEN, and a combination of 10 uM ER and 
10 uM GEN for 24 hours, 48 hours, and 72 hours. This technique identifies changes in 
the proportion of cells in each of the phases of the cell cycle as demonstrated in Figure 6 
adapted from (Ormerod, 2008). First, ER treated samples demonstrated a greater 
proportion of cells in the G2/M and S phases, most robustly after 72 hours of treatment 
(Figure 7).  There were no dramatic differences between the GEN treated cells and 
control at any of the time points tested.  The combination of ER and GEN demonstrated a 
similar pattern of accumulation in the G2/M and S phases as ER alone.  
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24h 48h 72h
Control
10uM	  Erucin
10uM	  Genistein
10uM	  Erucin +	  10um	  Genistein
Figure 6. Profile of flow cytometry histogram with phases of the cell cycle (Adapted 
from Flow Cytometry: A Basic Introduction ed. Michael G. Omerod) 
Figure 7. Erucin, alone and in combination with Genistein impacts cell cycle 
progression. 
Cell cycle profiles of cells treated daily suggest that Erucin (10uM) alone and in 
combination with Genistein (10um) induces accumulation in the S and G2/M phases of the 
cell cycle.  
	   20	  
 Because of the unique pattern of time and dose responses between ER and GEN 
and the response with co-treatment, we tested the sustained response of ER and GEN 
using a pre-treatment approach.  Cells were plated for 24 hours then pre-treated for 24 
hours with 10uM ER. After the 24 hour pre-treatment, media was removed and replaced 
with media containing 0, 5, 10 and 20uM GEN.  Cell viability was analyzed at 24, 48, 
and 72 hours after the initiation of GEN treatment.  As anticipated, there was a time and 
GEN dose dependent decrease in viability (p<0.001) Interestingly, pre-treatment with ER 
resulted in significantly less viability than with any GEN dose alone (p<0.001), Pre-
treatment with 10 uM ER and 20uM GEN decreased cell viability by 42.6%, 55.6%, and 
55.7% at 24, 48 and 72 hours. Without pre-treatment, 20 uM GEN decreased cell 
viability by 7.7%, 32.6%, and 24.2% at 24, 48 and 72 hours.  Figure 8 shows pre-
treatment with erucin at 24, 48 and 72 hours. 
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Figure 8. Pre-treatment with 10 uM Erucin causes sustained inhibition in viability 
maintained through 72h. 
Pre-treatment with Erucin for 24h before treatment with Genistein significantly decreased 
cell viability compared to treatment of Genistein alone. Main effects of time, pre-treatment 
and doses of genistein significant (p<0.001). *indicates significance (p<0.050) from no 
genistein; # indicates significance (p<0.05) from no erucin pre-treatment.  
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 To investigate the sustained influence of pre-treatment with GEN on the dose and 
time dependent response to ER, we pretreated PC-3 cells with 10 uM GEN for 24 hours, 
followed by treatment with 5, 10 and 20 uM ER for 24, 48 and 72 hours. As anticipated, 
the main effect for time and dose of ER was significant with p<0.001. Alternative to the 
effect of pre-treatment with ER, pre-treatment with GEN only modestly decreased 
viability after 24h, and was significant with p=0.006. At 24, 48 and 72 hours, cells pre-
treated with 10 uM GEN and 20 uM ER decreased in viability by 34.4%, 50.6%, and 
64.3% respectively. Without pre-treatment, 20 ER alone at 24, 48 and 72 hours decreased 
viability by 40.7%, 49.3%, and 57.2% respectively. Figure 9 shows pre-treatment with 
genistein at 24, 48 and 72 hours. 
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Figure 9. Pre-treatment with 10 uM Genistein modestly enhances the inhibitory 
activity of genistein.  
Pre-treatment with Genistein before Erucin was only modestly different at 48h when 
combined. The main effect of time and doses of Erucin were significant (p<0.001) and pre-
treatment modestly significant at 48h (p=0.002) and 72h (p=0.032). *indicates significance 
(p<0.05) from no erucin; # indicates significance (p<0.05) from no genistein pre-treatment.  	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V. Discussion 
These studies were designed to investigate the anti prostate cancer activity of 
known bioactive phytochemicals in cruciferous vegetables, including arugula and 
broccoli alone and in combination with the bioactive soy phytochemical, GEN.  The 
results of these studies clearly demonstrate that in the PC-3  in vitro model of prostate 
cancer, SFN, ER, and GEN exhibit dose dependent decreases in viability that become 
more robust over time.   
Both SFN and ER resulted in significant inhibition in viability within 24 hours of 
treatment. Treatment with 5 uM of either SFN or ER significantly reduced viability at 24. 
This data is consistent with the work of Melchini et al, 2009 demonstrating equal 
inhibition of cell viability by SFN and ER on the A549 human lung adenocarcinoma cell 
line. In the lung cancer model, this inhibition was associated with increases in p53 and 
p21 expression and induction of apoptosis as detected by PARP cleavage. In Caco-2 
human colon adenocarcinoma cells, ER was more effective than SFN at inducing phase II 
enzyme transcriptional activation, inducing G2/M cell cycle arrest, and apoptosis 
(Jakubikova et al, 2005).  Therefore, based upon these published comparisons of ER and 
SFN, we focused on ER for subsequent analyses investigating the effect of combining 
genistein to an ITC. 
 First, genistein alone inhibited viability in a time and dose dependant manner, 
however, it was less robust and delayed compared to either ER or SFN. Treatment with 
40 uM reduced viability first after 48 hours of treatment, and 10, 20 and 40uM reduced 
viability only after 72 hours of treatment. It is suggested that in prostate cancer cells, 
genistein treatments result in altered signaling pathways, such as the tyrosine kinase 
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pathway (Sanjeev et al, 2008). 
Clearly, the addition of ER to GEN enhanced the modest but significant inhibitory 
activity of GEN. However, the addition of GEN to different doses of ER were not 
significantly different, possibly due to the different mechanisms of ER and GEN on 
inhibiting cell proliferation, as well as the difference in the length of treatment time 
before there is a significant impact on viability. GEN, without ER, significantly inhibited 
cell viability at a 10uM dose after 72h.  This is the first set of experiments to combine ER 
with GEN and it is clear that the mechanism of action of these two compounds are quite 
different and further studies are under way to investigate the underlying mechanisms 
alone and in combination in a model of prostate cancer. 
We tested the impact of ER and GEN, alone and in combination, on progression 
through the cell cycle. These results suggest that ER alone and ER + GEN both resulted 
in accumulation in G2/M and S phases. These accumulations in these phases of the cell 
cycle are supportive of prior studies demonstrating that treatment with ITCs including 
SFN and ER alter mechanisms, including epigenetic modifications, necessary for 
progression through the cell cycle, subsequently inhibit proliferation (Jakubikova et al, 
2005) (Singh et al, 2009). 
Because of the unique patterns in the time dependent response between ER and 
GEN, we tested the impact of pre-treatment of one followed by treatment with the other. 
Most interesting, pre-treatment with ER for 24 hours resulted in significant differences in 
viability that was maintained for 72 hours, even after ER was removed. It was surprising 
how modest the effect of pre-treatment with GEN for 24 hours was in comparison to pre-
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treatment with ER. The decrease in viability with GEN pre-treatment was not maintained 
through 72 hours, unlike the pre-treatment with ER.  
The robust response of prostate cancer cells to SFN and ER is supportive of their 
potential role in the reduction of risk and use in prevention based clinical trials. Whole 
foods contain many components including a multitude of ITCs and indole-3-carbinol that 
alone and in combinations have a collective impact on cancer. Therefore, the next step is 
to use cruciferous vegetable extracts to determine their impact on viability alone and with 
the more complex soy extract.  We hypothesize that the whole food extracts would be 
more effective than the individual compounds due to the other components they provide.  
This in vitro model, ideal for initial investigations of anti-cancer activity focusing 
upon proliferation and apoptosis and additional mechanisms, does not adequately model 
the impact of any intervention on cancer prevention. Therefore, future directions also 
include testing the individual compounds, unique combinations, and / or whole food 
extracts in models of carcinogenesis testing the impact on prevention.  Some such models 
include the popular TRAMP, Pten, Nkx3.1 mouse models (Hensley and Kyprianou, 
2012), many of which have been used in nutrition based intervention trials (Keum et al, 
2009) (Pannellini et al, 2010). 
It would be narrow minded to make the assumption that the only anti-cancer 
activity is on the cancer cells themselves.  Ultimately, in vivo, these bioactive compounds 
have systemic effects including the tumor cells, the surrounding matrix, the vasculature 
supporting the growth of a tumor, and anti-cancer immunity. These studies presented here 
are supportive of moving forward with more complex food products (pure compounds vs 
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extracts), pre-clinical systems (animal models of prevention), and systems biology 
investigations (ie. Immune response and angiogenesis).  In addition to investigating the 
mechanism of action, the ability to integrate cruciferous vegetables into novel food 
products providing a safe product of bioavailable phytochemicals at physiological doses 
in a palatable form is an additional layer of complexity under investigation. 
 
VI. Significance 
 
While common, prostate cancer is considered a disease of aging and for most men 
frequently involves a slow, indolent progression. However, for some men, the cancer 
develops aggressively. There are multiple, effective treatment strategies for prostate 
cancer yet these include dramatic side effects that impact the quality of life. Therefore, 
effective prevention strategies are needed. As the long term goal is to integrate 
cruciferous vegetables into a vegetable juice that can be used for prevention based 
clinical trials.  We anticipate that this data will be used in our future studies to determine 
if arugula can be incorporated into our novel tomato soy juice that is designed for future 
cancer prevention clinical trials. These functional foods may provide overlapping 
mechanisms for prevention of carcinogenesis, which will need to be investigated further 
as these foods are developed. Although this study focused on prostate cancer cell 
progression, the phytochemicals in these vegetables have been shown to be effective in 
multiple malignancies, such as breast, colon and lung cancers (Melchini & Traka, 2010) 
and, therefore, the functional food product may be beneficial patients with for many types 
of cancer.  
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